title: [Sustained-release progesterone vaginal suppositories 3-development and clinical feasibility testing].
abstract: Although progesterone vaginal suppositories (hospital-formulated) are used for the treatment of infertility, their half-life is so short that multiple doses are required. In this study, we aimed to develop sustained-release vaginal suppositories suitable for clinical use which maintain an effective blood concentration by once-a-day treatment, and prepared 7 types of suppository containing the sustained-release progesterone tablets to characterize their sustained-release performance. We selected one candidate suppository among them, taking recovery rate, reproducibility, and hardness, as well as the sustained-release performance into consideration. The shell of the selected suppository is composed of VOSCO S-55 and progesterone for rapid release. The molded progesterone tablets for sustained release were embedded inside. The distribution of the weight and content of the suppository was limited, and the release rate of progesterone was significantly slower than that of a conventional progesterone suppository prepared in our hospital. The single-dose administration of the selected suppository to five healthy volunteers led to significant extension of the blood concentration. We also confirmed the rise of the basic value by multiple administration. The simulation comparison suggested that the blood progesterone concentration is controlled by once-a-day administration of the selected suppository better than twice-a-day administration of the conventional suppository. In conclusion, the sustained-release vaginal suppository prepared in this study was considered to be useful for clinical treatment.
authors.affiliation: Department of Pharmacy, Hoshigaoka Maternity Hospital, 27 Inoue-cho, Chikusa-ku, Nagoya 464-0026, Japan. hoshiya@toukeikai.com
authors.forename: Ayako
authors.initials: A
authors.lastname: Nakayama
authors.forename: Naho
authors.initials: N
authors.lastname: Yamaguchi
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Ohno
authors.forename: Chihiro
authors.initials: C
authors.lastname: Miyata
authors.forename: Haruomi
authors.initials: H
authors.lastname: Kondo
authors.forename: Hisakazu
authors.initials: H
authors.lastname: Sunada
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Okamoto
mesh_terms: D000328:Adult; D003692:Delayed-Action Preparations; D005240:Feasibility Studies; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage* / Q000097:blood; D005572:Formularies, Hospital as Topic; D006801:Humans; D008183:Luteal Phase / Q000097:blood; D008593:Menopause / Q000097:blood; D008875:Middle Aged; D011374:Progesterone / Q000008:administration & dosage* / Q000097:blood*; D011372:Progestins / Q000008:administration & dosage* / Q000097:blood; D013488:Suppositories
chemical_list: D003692:Delayed-Action Preparations; D005300:Fertility Agents, Female; D011372:Progestins; D013488:Suppositories; D011374:Progesterone